Latham & Watkins Advises on HealthCare Royalty’s Monetization Agreement for Modeyso® Commercial Royalties

HealthCare Royalty (HCRx) announced that it has entered into a royalty monetization agreement with the advisory group representing the former Oncoceutics Inc. securityholders for an undisclosed percentage of royalties on Modeyso® (dordaviprone) commercial sales. Modeyso received US FDA accelerated approval in August 2025 for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso is commercialized by Jazz Pharmaceuticals.

Latham & Watkins LLP represents the advisory group representing the former Oncoceutics Inc. securityholders in the transaction with a corporate deal team led by Bay Area partner Todd Trattner, with associates Axel Magnusson and Will Sedgwick. Advice was also provided on tax matters by Los Angeles partner Eric Cho.